Catalyst Biosciences: Rare Risk/Reward Opportunity
Seeking Alpha
NovoSeven was approved by the FDA in 1999 and the treatment has since been approved for use in individuals with Factor VII deficiency and Glanzmann's thrombasthenia. Shire's (SHPG) FEIBA is a plasma-based composition of coagulation factors …